Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistance

Award Number: R15GM144862
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2021
PERIOD OF PERFORMANCE END DATE: 08/31/2025

Group Awards By:

View Award Description

Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistance - ABSTRACT Globally, approximately 2.8M people are infected with bacteria that are deemed resistant to clinically relevant antibiotics an annual basis. Of these infections, 700,000 individuals will die with the United Sates accounting for 5% (35,000) of these deaths. In the 2019 report, The World Health Organization states that if no action is take, drug resistant diseases could cause 10 million deaths each year by 2050 and that by 2030, antibiotic resistance could force up to 24 million people into extreme poverty. There is an urgent need for the development of novel antibiotics to combat the drastic rise in the number of antibiotic resistant bacteria. In particular, there are few molecules with broad spectrum activity against multidrug resistant pathogens. One of the bottlenecks that is impeding the further development of novel antibiotics is the lack of identified gene clusters producing them, which could lead to optimized heterologous production. The overarching goal of this proposal is to identify and characterize the biosynthetic gene clusters and products from these anabolic pathways that responsible for the production of antibiotics, which in crude extracts were shown to be active in killing multi-drug resistant pathogens. The proposed research is significant since antibiotic resistance to clinically relevant antibiotics is increasing across different types of pathogenic bacteria, and particularly, broad-spectrum options to treat multidrug resistant strains are currently limited. The PI and his students recently isolated and identified several strains of rhizospheric bacteria, which possess broad-spectrum antibiotic activity. These initial experiments were performed using a culture-based approach, which screened for strains competing against each other on solid media, leveraging the chemical ecological concept of competition between bacterial species from the same environmental sample. One of the strains, Exiguobacterium sp RIT 594 produces a cocktail of antibiotic compounds (in response to another isolate Acinetobacter sp RIT 592). The antibiotic activity produce a >6 log reductions in three relevant resistant clinical isolates: (1) the epidemic strain MRSA USA300 (FPR3757), (2) NDM-producing E. coli (MCR1_NJ) and (3) VIM-producing P. aeruginosa (AR-0266) in 24 h time kill assays. Importantly, the preliminary data show that the emergence of in vitro resistance was not detected in the time kill assays. Subsequent analysis of crude extracts using LC-MS provided evidence and identified more than 200 novel compounds that are unknown in the mass spectrometry databases. Whole genome sequencing and annotation, revealed 8 putative gene clusters that contained a large number of uncharacterized proteins that are predicated to produce a variety of secondary metabolites that are putatively endowed with antibiotic properties.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$1,154 )
2026	2021	ROCHESTER INSTITUTE OF TECHNOLOGY	1 LOMB MEMORIAL DR	ROCHESTER	NY	14623	MONROE	USA	Biomedical Research and Research Training	000	1	2/17/2026	NEW	-$1,154
														Subtotal = -$1,154

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	ROCHESTER INSTITUTE OF TECHNOLOGY	1 LOMB MEMORIAL DR	ROCHESTER	NY	14623	MONROE	USA	Biomedical Research and Research Training	001	1	8/23/2024	SUPPLEMENT FOR EXPANSION	$0
2024	2021	ROCHESTER INSTITUTE OF TECHNOLOGY	1 LOMB MEMORIAL DR	ROCHESTER	NY	14623	MONROE	USA	Biomedical Research and Research Training	000	1	8/23/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $100,000 )
2022	2022	ROCHESTER INSTITUTE OF TECHNOLOGY (INC)	1 LOMB MEMORIAL DR	ROCHESTER	NY	14623	MONROE	USA	Biomedical Research and Research Training	000	1	6/3/2022	SUPPLEMENT FOR EXPANSION	$100,000
														Subtotal = $100,000

Issue Date FY: 2021 ( Subtotal = $443,583 )
2021	2021	ROCHESTER INSTITUTE OF TECHNOLOGY (INC)	1 LOMB MEMORIAL DR	ROCHESTER	NY	14623	MONROE	USA	Biomedical Research and Research Training	000	1	9/9/2021	NEW	$443,583
														Subtotal = $443,583

Grand Total All Awards = $542,429

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Isolation, identification and characterization of potentially novel antibiotics from rhizospheric bacteria without detectable in vitro resistance

Award Number: R15GM144862

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2021

PERIOD OF PERFORMANCE END DATE: 08/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer